Drug Trial Radar · NCT04792489
DALY II USA/ MB-CART2019.1 for DLBCL
Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
315
Planned (sponsor's estimate)
Start
May 25, 2021
Primary completion
Dec 31, 2026
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Miltenyi Biomedicine GmbHIndustry
- Sponsor type
- Industry
- First posted
- Mar 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts include subjects with diffuse large B-cell lymphoma (DLBCL) after receiving at least 2 lines of therapy, primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL) after receiving at least one line of therapy, mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least one line of therapy, and DLBCL transplant-ineligible after receiving at least one line of therapy.
Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Relapsed Diffuse Large B Cell Lymphoma
- High Grade B-cell Lymphoma (HGBCL)
- Primary Mediastinal B-cell Lymphoma (PMBCL)
- Transformed Lymphoma
- Central Nervous System Lymphoma
- Mantle Cell Lymphoma (MCL)
- Richter Transformation
- Transplant-ineligible 2nd Line DLBCL
Interventions
zamtocabtagene autoleucel (MB-CART2019.1)Biological
Chimeric antigen receptor (CAR) T cell therapy
CyclophosphamideDrug
Lymphodepleting chemotherapy
FludarabineDrug
Lymphodepleting chemotherapy
BendamustineDrug
Lymphodepleting chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: through study completion, up to 2 years
Locations
32 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
Mayo Clinic
Phoenix, Arizona · Recruiting
UC San Diego Health
La Jolla, California · Recruiting
Stanford University
Stanford, California · Recruiting
Colorado Blood Cancer Institute
Denver, Colorado · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Baptist Health Miami Cancer Institute
Miami, Florida · Recruiting
Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
Georgia Cancer Center at Augusta University
Augusta, Georgia · Recruiting
Robert H Lurie Cancer Center
Chicago, Illinois · Recruiting
University of Kansas Cancer Center
Westwood, Kansas · Recruiting
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, Maryland · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Washington University, St. Louis
St Louis, Missouri · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Terminated
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Duke University Medical Center - Division of Hematologic Malignancies
Durham, North Carolina · Recruiting
The Ohio State University Wexner Medical Center James Cancer
Columbus, Ohio · Recruiting
Oregon Health and Science University Knight Cancer Institute
Portland, Oregon · Recruiting
Allegheny Health Network Cancer Institute
Pittsburgh, Pennsylvania · Recruiting
University of Pittsburgh - Hillman Cancer Center
Pittsburgh, Pennsylvania · Withdrawn
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
UT Southwestern Medical Center
Dallas, Texas · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Texas Transplant Institute
San Antonio, Texas · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
University of Alberta Cross Cancer Institute
Edmonton, Alberta, Canada · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.